Amenamevir by Ugi-4CR
Open Access
- 1 February 2023
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Green Chemistry
- Vol. 25 (4) , 1322-1325
Abstract
We report a concise, convenient and sustainable multicomponent reaction synthesis of the approved anti-herpes zoster drug, Amenamevir.Keywords
Funding Information
- China Scholarship Council
This publication has 17 references indexed in Scilit:
- Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitorAntiviral Research, 2017
- Development of Scalable Conditions for the Ugi Reaction—Application to the Synthesis of (R)-LacosamideOrganic Process Research & Development, 2015
- Modern multicomponent reactions for better drug synthesesOrganic Chemistry Frontiers, 2014
- Multicomponent reactions: advanced tools for sustainable organic synthesisGreen Chemistry, 2014
- Chemistry and Biology Of Multicomponent ReactionsChemical Reviews, 2012
- Efficient Multicomponent Reaction Synthesis of the Schistosomiasis Drug PraziquantelChemistry – A European Journal, 2010
- Praziquantel and SchistosomiasisChemMedChem, 2010
- ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2Journal of Antimicrobial Chemotherapy, 2010
- New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex diseaseNature Medicine, 2002
- Herpes simplex virus helicase-primase inhibitors are active in animal models of human diseaseNature Medicine, 2002